These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 981320)
1. Clinical and biochemical parameters during neuroleptic treatment. I. Investigations with haloperidol. Rüther E; Schilkrut R; Ackenheil M; Eben E; Hippius H Pharmakopsychiatr Neuropsychopharmakol; 1976 Jan; 9(1):33-6. PubMed ID: 981320 [TBL] [Abstract][Full Text] [Related]
2. Clinical and biochemical parameters during neuroleptic treatment. II. Antipsychotic effect of haloperidol in patients with chronic organic brain damage. Schilkrut R; Rüther E; Ackenheil M; Eben E; Hippius H Pharmakopsychiatr Neuropsychopharmakol; 1976 Jan; 9(1):37-42. PubMed ID: 981321 [TBL] [Abstract][Full Text] [Related]
3. Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients. Gerlach J; Thorsen K; Fog R Psychopharmacologia; 1975; 40(4):341-50. PubMed ID: 1096218 [TBL] [Abstract][Full Text] [Related]
4. Concentrations of monoamine metabolites and chlorpromazine in cerebrospinal fluid for prediction of therapeutic response in psychotic patients treated with neuroleptic drugs. Sedvall G Prog Biochem Pharmacol; 1980; 16():133-40. PubMed ID: 6160594 [TBL] [Abstract][Full Text] [Related]
5. CSF-changes of HVA and 5-HIAA during intermittent and continuous Parkinson therapy with particular regard to prodipin application. Oppel F; Schulze G Pharmakopsychiatr Neuropsychopharmakol; 1978 Mar; 11(2):76-80. PubMed ID: 347467 [TBL] [Abstract][Full Text] [Related]
6. Clinical and biochemical parameters during neuroleptic treatment. III. Primitive reflexes during neuroleptic treatment. Schilkrut R; Rüther E; Ackenheil M; Eben E; Hippius H Pharmakopsychiatr Neuropsychopharmakol; 1976 Jan; 9(1):43-7. PubMed ID: 981322 [TBL] [Abstract][Full Text] [Related]
7. [Cerebrospinal HVA and 5-HIAA in patients with endogenous depression in the course of treatment]. Loeb DC; Roccatagliata G; Albano C; Abbruzzese G Schweiz Arch Neurol Neurochir Psychiatr; 1980; 126(1):27-32. PubMed ID: 6158092 [TBL] [Abstract][Full Text] [Related]
8. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment. Kahn RS; Davidson M; Knott P; Stern RG; Apter S; Davis KL Arch Gen Psychiatry; 1993 Aug; 50(8):599-605. PubMed ID: 7688208 [TBL] [Abstract][Full Text] [Related]
9. CSF amine metabolites, clinical symptoms, and body movement in psychiatric patients. Kirstein L; Bowers MB; Heninger G Biol Psychiatry; 1976 Aug; 11(4):421-34. PubMed ID: 963133 [TBL] [Abstract][Full Text] [Related]
10. Treatment of non-fluctuating progressive dystonia: a neuropharmacological approach. Willemse J; van Nieuwenhuizen O; Gooskens RH; Westenberg HG Neuropediatrics; 1984 Oct; 15(4):208-10. PubMed ID: 6208504 [TBL] [Abstract][Full Text] [Related]
11. The effect of dexamethasone on cerebrospinal fluid monoamine metabolites and cortisol in psychiatric patients. Banki CM; Arató M; Papp Z; Kurcz M Pharmacopsychiatria; 1983 May; 16(3):77-81. PubMed ID: 6193544 [TBL] [Abstract][Full Text] [Related]
12. [HVA and 5-HIAA in the cerebrospinal fluid in extrapyramidal and cerebrellar syndromes. Preliminary data]. Carrieri P; Mandarini A; Campanella G Acta Neurol (Napoli); 1975; 30(5):449-54. PubMed ID: 132845 [No Abstract] [Full Text] [Related]
13. [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study]. Scatton B; Zarifian E; Bianchetti G; Cuche H; Loo H; Morselli PL Encephale; 1982; 8(1):1-8. PubMed ID: 7094868 [TBL] [Abstract][Full Text] [Related]
14. [Biochemical mechanisms of extrapyramidal-motoric effect of haloperidol in man]. Eben E; Ackenheil M; Raese J; Rüther E Arzneimittelforschung; 1974 Aug; 24(8):1133-5. PubMed ID: 4479374 [No Abstract] [Full Text] [Related]
15. Analysis of neurotransmitter metabolites and adenosine 3',5'-monophosphate in the CSF of patients with extrapyramidal motor disorders. Cramer H; Warter JM; Renaud B Adv Neurol; 1984; 40():431-5. PubMed ID: 6198888 [No Abstract] [Full Text] [Related]
16. Monoamine metabolites in normal human cerebrospinal fluid and in degenerative diseases of the central nervous system. González-Quevedo A; García JC; Fernández R; Fernández Cartaya L Bol Estud Med Biol; 1993; 41(1-4):13-9. PubMed ID: 7521168 [TBL] [Abstract][Full Text] [Related]
17. [A study of clinical pictures and monoamine metabolism of Gilles de la Tourette syndrome]. Takano K; Ishiguro T Seishin Shinkeigaku Zasshi; 1993; 95(1):1-29. PubMed ID: 7685527 [TBL] [Abstract][Full Text] [Related]
18. Effect of chlorpromazine treatment on monoamine metabolite levels in cerebrospinal fluid of psychotic patients. Wode-Helgodt B; Fyrö B; Gullberg B; Sedvall G Acta Psychiatr Scand; 1977 Aug; 56(2):129-42. PubMed ID: 899844 [TBL] [Abstract][Full Text] [Related]
19. Monoamine metabolites in successive samples of spinal fluid. A comparison between healthy volunteers and patients with multiple sclerosis. Andersen O; Johansson BB; Svennerholm L Acta Neurol Scand; 1981 Apr; 63(4):247-54. PubMed ID: 6163303 [TBL] [Abstract][Full Text] [Related]
20. [Homovanillic (HVA) and 5-hydroxyindoleacetic (5-HIAA) acid concentration in the cerebrospinal fluid of patients with supratentorial tumors and symptoms of intracranial hypertension (preliminary report)]. Majchrzak H; Kmieciak-Kołada K; Herman Z; Wencel T Neurol Neurochir Pol; 1980; 14(1):87-90. PubMed ID: 6154903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]